Skip to content

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02121158
Acronym
I-70
Enrollment
167
Registered
2014-04-23
Start date
2015-08-07
Completion date
2020-11-06
Last updated
2024-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction

Keywords

CSP 592, ICD, cardiovascular, heart, aging, chronic diseases, multi-site trial, investigational device, cardiomyopathy, coronary artery disease, congestive heart failure, myocardial infarction, I-70, I70, elderly, defibrillator

Brief summary

The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death in patients 70 years and older. This study will assess the many competing factors involved with ICD implantation including 1) the impact on mortality, especially in the context of a declining rate of sudden death with advanced age, 2) the tolerability of the powerful therapeutic action of the device, and 3) the impact on quality of life.

Detailed description

The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death (SCD) in patients 70 years and older. In particular, this study is designed to determine the comparative effectiveness of ICD, in addition to optimal medical therapy (OMT), in reducing all-cause mortality, versus OMT alone; OMT includes standard intervention for chronic heart failure patients, i.e. lifestyle modification, disease management, adoption of healthy diet and exercise practices, etcetera. One particularly important secondary objective is to assess treatment efficacy under the conditions of high versus low co-morbidity burden. Participants will be randomized (1:1 ratio) to ICD + OMT or OMT alone, and stratified by participating site and co-morbidity level (Charlson score \<3 versus 3+). Acute treatment visits will occur as clinically indicated and per local convention; follow-up will occur 1-4 months post-randomization (all participants), and not sooner than 30 days - and not later than 120 days post-implantation (ICD arm); regular follow-up will occur at 6 month intervals post-randomization until study close (all participants). All follow-up will be conducted centrally. Neither the participant nor treating clinician will be masked to treatment. Primary Objective: The primary objective of this study is to determine if a primary prevention strategy with ICD implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause mortality compared to OMT alone in patients 70 years of age and older who are eligible for ICD therapy according to current Centers for Medicare & Medicaid Services (CMS) criteria. Primary Hypothesis: The primary hypothesis of this study is that implantation of an ICD plus optimal medical therapy will reduce all-cause mortality in patients 70 years of age and older versus optimal medical therapy alone. Secondary Objectives: 1. One secondary objective of this study is to ascertain whether age, co-morbidity burden, or age and burden together, are determinants in mortality outcomes in the OMT versus ICD + OMT group. 2. An additional secondary objective of the study is to determine the effect of ICD implantation plus optimal medical therapy on quality of life among elderly patients compared with optimal medical therapy alone.

Interventions

DEVICEImplantable Cardioverter Defibrillator

The ICD and lead(s) will be FDA-approved.

OTHEROptimal Medical Therapy

Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 70 years of age or older 2. Eligible for ICD implementation according to the CMS criteria for primary prevention by one of the following conditions: 1. Documented prior MI and a measured left ventricular ejection fraction (LVEF) \<=30% (includes New York Heart Association \[NYHA\] class I, II, or III) 2. Coronary artery disease with a documented prior MI, a measured left ventricular ejection fraction \<=35%, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) at electrophysiology (EP) study 3. Ischemic dilated cardiomyopathy (IDCM), documented prior MI, NYHA class II and III heart failure, and measured LVEF \<=35% 4. Non-ischemic dilated cardiomyopathy (NIDCM) \> 3 months, NYHA Class II and III heart failure, and measured LVEF \<=35% 3. Stable condition on Optimal Medical Therapy 4. Able and willing to provide informed consent to participate in this study

Exclusion criteria

1. Enrolled in or planning to enroll in a conflicting trial 2. Receiving a bi-ventricular ICD device 3. New York Heart Association class IV heart failure 4. Cardiogenic shock or symptomatic hypotension while in stable baseline rhythm, 5. Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months 6. An MI within the past 40 days 7. Clinical symptoms or findings that would make them a candidate for coronary revascularization 8. Irreversible brain damage from pre-existing cerebral disease 9. Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year 10. Circumstance that would prevent completion of the trial and follow-up activities, including medical condition

Design outcomes

Primary

MeasureTime frameDescription
MortalityThrough study completion, starting from consent/baseline: average of 31 months.All-cause mortality

Secondary

MeasureTime frameDescription
Quality of Life - Minnesota Living With Heart Failure QuestionnaireMeasured at 12-months post-randomizationMinnesota Living with Heart Failure questionnaire. MLHF scoring: 0 points = Best QOL, 105 points = Worst QOL.
Sudden Cardiac DeathThrough study completion, starting from consent/baseline: average of 31 months.Sudden Cardiac Death
All-cause HospitalizationThrough study completion, starting from consent/baseline: average of 31 months.Number of participants hospitalized during study follow-up

Countries

United States

Participant flow

Recruitment details

Recruitment at six Department of Veterans Affairs Medical Centers (VAMCs). Recruitment start: 8/6/2015 (4) 9/25/2015 (1) and 10/29/2015 (1). Recruitment terminated: 12/6/2016 (1) and 12/5/2019 (5).

Pre-assignment details

None: Study design did not include significant events that occur after participant enrollment: no run-in phase, nor wash-out.

Participants by arm

ArmCount
Optimal Medical Therapy
Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
85
Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)
Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke + FDA-Approved implantable cardioverter defibrillator and leads.
82
Total167

Baseline characteristics

CharacteristicOptimal Medical TherapyOptimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
85 Participants82 Participants167 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
New York Heart Association Class: I2 Participants4 Participants6 Participants
New York Heart Association Class: II62 Participants58 Participants120 Participants
New York Heart Association Class: III21 Participants20 Participants41 Participants
New York Heart Association Class: IV0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
12 Participants15 Participants27 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
73 Participants67 Participants140 Participants
Region of Enrollment
United States
85 Participants82 Participants167 Participants
Sex: Female, Male
Female
1 Participants1 Participants2 Participants
Sex: Female, Male
Male
84 Participants81 Participants165 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
23 / 8520 / 82
other
Total, other adverse events
1 / 856 / 82
serious
Total, serious adverse events
67 / 8562 / 82

Outcome results

Primary

Mortality

All-cause mortality

Time frame: Through study completion, starting from consent/baseline: average of 31 months.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Optimal Medical TherapyMortality23 Participants
Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)Mortality20 Participants
Secondary

All-cause Hospitalization

Number of participants hospitalized during study follow-up

Time frame: Through study completion, starting from consent/baseline: average of 31 months.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Optimal Medical TherapyAll-cause Hospitalization61 Participants
Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)All-cause Hospitalization60 Participants
p-value: 0.745795% CI: [0.534, 1.568]Cox Proportional Hazards
Secondary

Quality of Life - Minnesota Living With Heart Failure Questionnaire

Minnesota Living with Heart Failure questionnaire. MLHF scoring: 0 points = Best QOL, 105 points = Worst QOL.

Time frame: Measured at 12-months post-randomization

Population: Analysis population differs from total number of study participants due to non-completion of the 12-month study visit, explained by either patient expiry or missed visit.

ArmMeasureValue (MEDIAN)
Optimal Medical TherapyQuality of Life - Minnesota Living With Heart Failure Questionnaire11 score on a scale
Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)Quality of Life - Minnesota Living With Heart Failure Questionnaire13 score on a scale
Secondary

Sudden Cardiac Death

Sudden Cardiac Death

Time frame: Through study completion, starting from consent/baseline: average of 31 months.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Optimal Medical TherapySudden Cardiac Death5 Participants
Optimal Medical Therapy + Implantable Cardioverter Defibrillator (OMT + ICD)Sudden Cardiac Death3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026